Evaluation of Interferon-Gamma Responses to HCMV Infection in HIV Positive Individuals

This study is currently recruiting participants.

Verified by The Alfred, May 2008

First Received: September 13, 2005 Last Updated: May 16, 2008 History of Changes

Sponsor:	The Alfred
Collaborator:	Cellestis
Information provided by:	The Alfred
ClinicalTrials.gov Identifier:	NCT00168259

Purpose

The study is designed to evaluate interferon responses to CMV in HIV positive individuals and a component will look at interferon responses to CMV in HIV positive individuals over time after commencement of antiretroviral therapy. We will also look at the correlation between CD4 T cell numbers and HLA type with the interferon response.

Condition
HIV Infection CMV Disease

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	Evaluation of Interferon-Gamma Responses to HCMV Infection in HIV Positive Individuals

Resource links provided by NLM:

MedlinePlus related topics: AIDS

Drug Information available for: Interferon gamma-1b Interferons

U.S. FDA Resources

Further study details as provided by The Alfred:

Biospecimen Retention: Samples With DNA

Biospecimen Description:

Plasma, and DNA

Estimated Enrollment:	20
Study Start Date:	December 2004

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

HIV infected patients with past CMV infection initiating antiretroviral therapy

Criteria

Inclusion Criteria:

HIV positive with history of documented HCV infection
> 18 years old
HIV positive
Antiretroviral, starting on therapy (cross sectional study)
> 18 years old (longitudinal study)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00168259

Contacts

Contact: Sharon Lewin, Professor

0061 3 9276 3009

Sharon.Lewin@alfred.org.au

Locations

Australia, Victoria
Alfred Hospital	Recruiting
Melbourne, Victoria, Australia, 3004
Contact: Sharon Lewin, Professor 0061 3 9276 3009 Sharon.Lewin@alfred.org.au

Sponsors and Collaborators

The Alfred

Cellestis

Investigators

Principal Investigator:

Sharon Lewin, Professor

The Alfred

More Information

No publications provided

Responsible Party:	The Alfred Hospital ( Professor Sharon Lewin )
Study ID Numbers:	185/04
Study First Received:	September 13, 2005
Last Updated:	May 16, 2008
ClinicalTrials.gov Identifier:	NCT00168259 History of Changes
Health Authority:	Australia: National Health and Medical Research Council

Keywords provided by The Alfred:

Treatment Naive
HIV

Additional relevant MeSH terms:

Anti-Infective Agents
Communicable Diseases
RNA Virus Infections
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Interferon Type II
Immune System Diseases
Antineoplastic Agents
Interferons
Acquired Immunodeficiency Syndrome
Infection

Antiviral Agents
Pharmacologic Actions
Immunologic Deficiency Syndromes
Virus Diseases
HIV Infections
Therapeutic Uses
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections
Interferon-gamma, Recombinant

ClinicalTrials.gov processed this record on February 08, 2010